FlandersBio on Twitter

Follow us on Twitter

Life sciences database

Databank life sciences

in het nederlands in english

FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.

FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.


Website: http://www.glpg.com
Phone: +32 15 34 29 00
FlandersBio Member
More address details

Business Focus

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.


Company Profile

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indication. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn’s disease. Galapagos reported good activity and a favorable safety profile in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis. Almost exclusively, these programs have derived from the propriety target discovery platform and is it Galapagos’ goal to develop these programs into best-in-class treatments. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.

Science & Technology or Services

Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers what proteins (‘targets’) play a role in diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos develops small molecules that inhibit these targets, restore the balance and thereby can positively influence the course of the disease. This approach is expected to yield a breakthrough in treatment by stopping the disease rather than just treating the symptoms. Galapagos’ aim is to make a lasting positive contribution to society at large.

More info

Address: Generaal De Wittelaan L11 A3
2800 Mechelen

Route: Via Google Maps
Website: http://www.glpg.com

Phone: +32 15 34 29 00
Fax: +32 15 34 29 01
Foundation date: 1/1999
Email: ir@glpg.com

Become a Member

Listen to some testimonials from companies that are a member of FlandersBio and discover the benefits of membership

Read more

Z Life Sciences

Looking behind the scenes of the vibrant life sciences sector in Flanders!



Belgian biotech on Euronext

Belgian biotech on Euronext

FlandersBio Members

Korn Ferry - Hay Group Greiner Bio-One B.V.B.A. PwC Belgium BSC Right Away Pepric The Clinical Company Ad Hoc Clinical Viziphar Biosciences COVARTIM Janssen Diagnostics Kinesis Pharma CATALISTI DuPont Industrial Biosciences Adagio Company PAREXEL Belgium Asclepia Pauwels Consulting PharmaFluidics Talentmark AIM iTeos Therapeutics SA Unitron Group 3D-PharmXchange SynAbs MouSensor Janssen Pharmaceutica Oblita Therapeutics

View all members

Life Sciences Map

Life Sciences Map

View Life Sciences Map

Back to top